CTOs on the Move

Axovant

www.axovant.com

 
Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. We aspire to lead the way into a new era of progress to protect the fullness of life for people living with neurologic conditions. We see the potential of compelling therapeutic pathways and set our sights high on creating life-changing advancement for millions of people affected by neurologic disorders.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.axovant.com
  • 11 Times Square 33rd Floor
    New York, NY USA 10036
  • Phone: 833.296.8268

Executives

Name Title Contact Details
John Wright
Chief Technology Officer Profile

Similar Companies

3B Scientific

The international group of companies 3B Scientific specializes in the manufacturing and marketing of didactic material for scientific, medical and patient education. The group`s oldest site in Budapest/Hungary began its manufacturing history in 1819, making 3B Scientific the most experienced group of companies in the industry. The mother company was founded 1948 in Hamburg by the 3 Bs: Mr. Paul Binhold, his wife Hedwig Binhold and their daughter Marion Binhold, now Marion Kurland.

SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.

InterVenn Biosciences

Clinical Glycoproteomics + Artificial Intelligence

Palladio Biosciences

Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.

Casma Therapeutics

New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.